These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas. Korones DN; Smith A; Foreman N; Bouffet E Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359 [TBL] [Abstract][Full Text] [Related]
50. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134 [TBL] [Abstract][Full Text] [Related]
51. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Sathornsumetee S; Cao Y; Marcello JE; Herndon JE; McLendon RE; Desjardins A; Friedman HS; Dewhirst MW; Vredenburgh JJ; Rich JN J Clin Oncol; 2008 Jan; 26(2):271-8. PubMed ID: 18182667 [TBL] [Abstract][Full Text] [Related]
52. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas. Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427 [TBL] [Abstract][Full Text] [Related]
53. Angiogenic inhibition in high-grade gliomas: past, present and future. Jo J; Schiff D; Purow B Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175 [TBL] [Abstract][Full Text] [Related]
54. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513 [TBL] [Abstract][Full Text] [Related]
55. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Miletic H; Niclou SP; Johansson M; Bjerkvig R Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067 [TBL] [Abstract][Full Text] [Related]
56. Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University. Roosen N; Kiwit JC; Lins E; Schirmer M; Bock WJ Cancer; 1989 Nov; 64(10):1984-94. PubMed ID: 2553234 [TBL] [Abstract][Full Text] [Related]
57. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. Hurwitz CA; Strauss LC; Kepner J; Kretschmar C; Harris MB; Friedman H; Kun L; Kadota R J Pediatr Hematol Oncol; 2001; 23(5):277-81. PubMed ID: 11464982 [TBL] [Abstract][Full Text] [Related]
58. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Kurz SC; Cabrera LP; Hastie D; Huang R; Unadkat P; Rinne M; Nayak L; Lee EQ; Reardon DA; Wen PY Neurology; 2018 Oct; 91(14):e1355-e1359. PubMed ID: 30171077 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. Yerram P; Reiss SN; Modelevsky L; Gavrilovic IT; Kaley T J Neurooncol; 2019 Oct; 145(1):57-63. PubMed ID: 31432377 [TBL] [Abstract][Full Text] [Related]
60. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]